Jan 2, 2019 7:00am EST Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
Dec 18, 2018 7:00am EST Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Nov 29, 2018 7:00am EST Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
Nov 9, 2018 7:30am EST Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
Nov 6, 2018 7:00am EST Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
Nov 1, 2018 7:00am EDT Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference